Find more results for XOMA

Officers and directors

W. Denman Van Ness
Lead Independent Chairman of the Board
James R. Neal
Chief Executive Officer, Chief Operating Officer, Director
Thomas M. Burns
Chief Financial Officer
Thomas Klein
Vice President, Chief Commercial Officer
Chris Wells
Vice President - Human Resources and Information Technology
Matthew Perry
John W. Varian
William K. Bowes Jr.
Independent Director
Peter Barton Hutt
Independent Director
Joseph M. Limber
Independent Director


2910 7th St
BERKELEY, CA 94710-2700
United States - Map
+1-510-6441170 (Phone)
+1-302-6555049 (Fax)

Website links

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Related companies

* Delayed by up to 20 minutes -  Disclaimer